Apollo Onyx Delivery Micro Catheter
Ev3 Neurovascular · Decision date Apr 9, 2026
What did the FDA decide?
FDA records P030004/S041 as a supplement to PMA P030004, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Apr 9, 2026.
FDA approval order statement
approval to replace manually operated components of the 2-Spindle Coil Winder with automated safety features and procedures using the new MCS 3-Spindle coil winder for the Apollo Onyx Delivery Micro Catheter
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Neurology
- Decision date
- Apr 9, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P030004/S041
- Regulatory pathway
- PMA supplement
- Applicant
- Ev3 Neurovascular
- Product code
- MFE
- Decision code
- OK30
- Decision date
- Apr 9, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Agent, injectable, embolic.
- Applicant
- Ev3 Neurovascular
- Product code
- MFE
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P030004. Subsequent supplements may change the device or its indications.
FDA decision timeline
P030004 · Original PMA
ONYX LIQUID EMBOLIC SYSTEM
P030004/S035 · Related supplement
Onyx Liquid Embolic System (LES)
P030004/S041 received
Application receipt date recorded by FDA.
P030004/S041 · FDA decision
30-Day Notice
P030004/S040 · Related supplement
Onyx Liquid Embolic System (LES)
P030004/S043 · Related supplement
Apollo Onyx Delivery Micro Catheter
P030004/S044 · Related supplement
Onyx Liquid Embolic System
P030004/S042 · Related supplement
Onyx Liquid Embolic System (LES)
P030004/S039 · Related supplement
Onyx Liquid Embolic System (Onyx LES)
Timeline entries are records held by MedtechLedger for P030004. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P030004
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
ONYX LIQUID EMBOLIC SYSTEMP030004 | Ev3 Neurovascular | PMA approval | Jul 21, 2005 | FDA |
Onyx Liquid Embolic System (LES)P030004/S035 | Ev3 Neurovascular | PMA supplement | Dec 8, 2025 | FDA |
Onyx Liquid Embolic System (LES)P030004/S040 | Ev3 Neurovascular | PMA supplement | Apr 29, 2026 | FDA |
Apollo Onyx Delivery Micro CatheterP030004/S043 | Ev3 Neurovascular | PMA supplement | May 26, 2026 | FDA |
Onyx Liquid Embolic SystemP030004/S044 | Ev3 Neurovascular | PMA supplement | Jul 21, 2026 | FDA |
Onyx Liquid Embolic System (LES)P030004/S042 | Ev3 Neurovascular | PMA supplement | Aug 5, 2026 | FDA |
Onyx Liquid Embolic System (Onyx LES)P030004/S039 | Ev3 Neurovascular | PMA supplement | Oct 14, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Ev3 Neurovascular
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 9775 Toledo Way, Irvine, CA, 92618
Sources and methodology
- Original FDA record: P030004/S041
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



